$16.410
+1.076 (+6.56%)收盤時
KLRA 同業比較
In the context of the broader market, KLRA competes directly with industry leaders such as COAG and ADMA. With a market capitalization of $2.13B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against COAG's N/A and ADMA's 69.31%. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Kailera Therapeutics Inc 財務表現
Kailera has reported significant net losses, with Q2 2026 showing a net income loss of $111.3 million and an EPS of -1.09, indicating ongoing financial struggles.
Financials
FY2026Q2
YoY:
+295.98%
-121.37M
Operating Profit
FY2026Q2
YoY:
+284.52%
-111.31M
Net Income after Tax
FY2026Q2
YoY:
+373.91%
-1.09
EPS - Diluted
FY2026Q1
-68.31M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。